Abstract
The purpose of this study was to assess the role of hepatic arterial embolization (HAE) and chemoembolization (HACE) in patients with large-volume liver metastases. Patients with metastatic neuroendocrine tumors, melanomas, or gastrointestinal stromal tumors (GISTs) with >75% liver involvement who underwent HAE or HACE were included in the study. Radiologic response, progression-free survival (PFS), overall survival (OS), and postprocedure complications were assessed. Sixty patients underwent 123 treatment sessions. Of the 48 patients for whom follow-up imaging was available, partial response was seen in 12 (25%) patients, minimal response in 6 (12%), stable disease in 22 (46%), and progressive disease in 8 (17%). Median OS and PFS were 9.3 and 4.9 months, respectively. Treatment resulted in radiologic response or disease stabilization in 82% and symptomatic response in 65% of patients with neuroendocrine tumors. Patients with neuroendocrine tumors had higher response rates (44% vs. 27% and 0%; p = 0.31) and longer PFS (9.2 vs. 2.0 and 2.3 months; p < 0.0001) and OS (17.9 vs. 2.4 and 2.3 months; p < 0.0001) compared to patients with melanomas and GISTs. Major complications occurred in 21 patients after 23 (19%) of the 123 sessions. Nine of the 12 patients who developed major complications resulting in death had additional risk factors—carcinoid heart disease, sepsis, rapidly worsening performance status, or anasarca. In conclusion, in patients with neuroendocrine tumors with >75% liver involvement, HAE/HACE resulted in symptom palliation and radiologic response or disease stabilization in the majority of patients. Patients with hepatic metastases from melanomas and GISTs, however, did not show any appreciable benefit from this procedure. Patients with massive liver tumor burden, who have additional risk factors, should not be subjected to HAE/HACE because of the high risk of procedure-related mortality.
Similar content being viewed by others
References
Carrasco CH, Chuang VP, Wallace S (1983) Apudomas metastatic to the liver: treatment by hepatic artery embolization. Radiology 149:79–83
Ajani J, Humberto C, Wallace S (1994) Neuroendocrine tumors metastatic to the liver: vascular occlusion therapy. Ann NY Acad Sci 733:479–487
Dominguez S, Denys A, Menu Y, Ruszniewski P (1999) Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Ital J Gastroenterol Hepatol 31(Suppl 2):S213–S215
Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83:2293–2301
Gupta S, Yao JC, Ahrar K, et al. (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M. D. Anderson experience. Cancer J 9:261–267
Gupta S, Johnson MM, Murthy R, et al. (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590–1602
Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, Woltering EA (1992) Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 163:479–483
Perry LJ, Stuart K, Stokes KR, Clouse ME (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116:1111–1116, discussion 1116–1117
Therasse E, Breittmayer F, Roche A, et al. (1993) Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 189:541–547
Roche A, Girish BV, de Baere T, et al. (2004) Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology 51:1751–1756
Roche A, Girish BV, de Baere T, et al. (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13:136–140
Moertel CG, Johnson CM, McKusick MA, et al. (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120:302–309
Bedikian AY, Legha SS, Mavligit G, et al. (1995) Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 76:1665–1670
Kobayashi K, Gupta S, Trent JC, et al. (2006) Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer 107:2833–2841
Mavligit GM, Pollock RE, Evans HL, Wallace S (1993) Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver. Cancer 72:375–380
Patel K, Sullivan K, Berd D, et al. (2005) Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 15:297–304
Touzios JG, Kiely JM, Pitt SC, et al. (2005) Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg 241:776–783, discussion 783–775
Chamberlain RS, Canes D, Brown KT, et al. (2000) Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 190:432–445
Gates J, Hartnell GG, Stuart KE, Clouse ME (1999) Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 19:399–414
Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF (2002) Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 13:S211–S221
Dodd GD, 3rd, Soulen MC, Kane RA, et al. (2000) Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 20:9–27
Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion 68:94–101
Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S (1986) The carcinoid syndrome: palliation by hepatic artery embolization. AJR 147:149–154
Kim YH, Ajani JA, Carrasco CH, et al. (1999) Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 17:474–478
Tellez C, Benson AB 3rd, Lyster MT, et al. (1998) Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82:1250–1259
Brown KT, Koh BY, Brody LA, et al. (1999) Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 10:397–403
Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S (2003) Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR 180:1379–1384
Charnsangavej C (1993) Chemoembolization of liver tumors. Semin Invest Radiol 10:150–160
Sanz-Altamira PM, Spence LD, Huberman MS, et al. (1997) Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum 40:770–775
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kamat, P.P., Gupta, S., Ensor, J.E. et al. Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases. Cardiovasc Intervent Radiol 31, 299–307 (2008). https://doi.org/10.1007/s00270-007-9186-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-007-9186-3